title: A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel.
abstract: BACKGROUND
  NUT midline carcinoma (NMC) is recognized as a very rare tumor that most often occurs around the midline and shows NUT rearrangement. This tumor affects children and younger adults, progresses rapidly, and shows an extremely poor prognosis, even with intensive chemotherapy. Very few reports have described effective treatment for this tumor.
  
  
  METHODS
  A 12-year-old girl with NMC was treated using cisplatin (CDDP), docetaxel, gemcitabine, pemetrexed, and vinorelbine.
  
  
  RESULTS
  Imaging showed partial response with CDDP and docetaxel, and complete response with gemcitabine. After reexacerbation of the tumor, although partial response was achieved with vinorelbine, the patient died 89 weeks after onset because of reexacerbation.
  
  
  CONCLUSIONS
  NMC is a very rare disease with poor prognosis. This study is the first to report response of NMC to gemcitabine and vinorelbine. The findings suggest that combination chemotherapies including CDDP, docetaxel, gemcitabine, and vinorelbine may be a choice in the treatment for NMC.
authors: Departments of *Pediatrics §Pathology ‡Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi †Department of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
authors: Hideaki
authors: H
authors: Ueki
authors: Naoko
authors: N
authors: Maeda
authors: Masahiro
authors: M
authors: Sekimizu
authors: Yuka
authors: Y
authors: Yamashita
authors: Suzuko
authors: S
authors: Moritani
authors: Keizo
authors: K
authors: Horibe
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012074:Remission Induction; D043823:Taxoids / Q000627:therapeutic use; D013899:Thoracic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; C471990:BRD4-NUT fusion oncogene protein, human; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D002945:Cisplatin; D000093542:Gemcitabine